SCHEMBL4666487

SCHEMBL4666487

Cc1cc2c(F)c(Oc3ccnc4cc(OCCn5ccnn5)c(C#N)cc34)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.53
PDGFRB P09619 3/20 0.53
FGFR1 P11362 4/20 0.43
FLT1 P17948 4/20 0.43
FGFR2 P21802 4/20 0.43
FGFR4 P22455 4/20 0.43
FGFR3 P22607 4/20 0.43
FLT4 P35916 4/20 0.43
RET P07949 2/20 0.43
EGFR P00533 2/20 0.43
SRC P12931 2/20 0.43
PLK4 O00444 1/20 0.43
GAK O14976 1/20 0.43
EPHB6 O15197 1/20 0.43
RIPK2 O43353 1/20 0.43
ERN1 O75460 1/20 0.43
STK10 O94804 1/20 0.43
MAP4K4 O95819 1/20 0.43
CHEK2 O96017 1/20 0.43
ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664094 0.96 KDR (0.52) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4666049 0.85 KDR (0.59) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4666011 0.83 KDR (0.61) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4664551 0.82 AXL (0.54) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4664119 0.82 KDR (0.66) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4666448 0.81 KDR (0.55) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4666068 0.80 KDR (0.55) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4667697 0.80 KDR (0.52) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4666031 0.79 KDR (0.53) KDRPDGFRBFGFR1FLT1FGFR2
SCHEMBL4666041 0.77 FLT1 (0.42) KDRPDGFRBFGFR1FLT1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 US claimed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 US claimed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 EP claimed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO claimed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 US disclosed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 EP disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 KDR 4/4885PDGFRB 282/4885FGFR1 99/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 KDR 5/4885PDGFRB 206/4885FGFR1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.